The development of immune-checkpoint inhibitors (ICIs) has heralded a new era in cancer
treatment, enabling the possibility of long-term survival in patients with metastatic disease …

Immune-related adverse events (irAEs) are a range of complications associated with the use
of immune-checkpoint inhibitors (ICIs). Two major classes of ICIs widely used are Cytotoxic …

Immune checkpoint inhibitors (ICIs) are the standard of care for the treatment of several
cancers. While these immunotherapies have improved patient outcomes in many clinical …

Background Immune checkpoint inhibitor-associated acute kidney injury (ICPi-AKI) has
emerged as an important toxicity among patients with cancer. Methods We collected data on …

Acute kidney injury (AKI) is a global health challenge of vast proportions, as approx. 13.3%
of people worldwide are affected annually. The pathophysiology of AKI is very complex, but …

Immune checkpoint inhibitors (ICIs) are a novel class of immunotherapy drugs that have
improved the treatment of a broad spectrum of cancers as metastatic melanoma, non-small …

Adverse events (AEs) related to the use of immune checkpoint inhibitor (ICI) therapy are
defined as immune-related (IR) AEs (irAEs). irAEs are graded according to the Common …

Onconephrology is a new subspecialty of nephrology that recognizes the important
intersections of kidney disease with cancer. This intersection takes many forms and includes …

Immune checkpoint inhibitors (ICIs) are widely used for various malignancies. However,
their safety and efficacy in patients with a kidney transplant have not been defined. To …

Introduction Immune checkpoint inhibitors (ICIs) are increasingly used to treat cancers.
Kidney immune-related adverse events (IRAEs) are now well recognized, with the incidence …